QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare ... ( QuatRx CEO will present an update on...)

QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference

Date:1/4/2008

QuatRx CEO will present an update on QuatRx clinical development programs including review of positive results from the Phase 3 pivotal trial for

Ophena(TM) (ospemifene)

ANN ARBOR, Mich., Jan. 4 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced that the company chief executive officer, Robert L. Zerbe, M.D., will be a presenter at the 26th Annual JP Morgan Healthcare Conference on Tuesday, January 8th, 2008, at 9:30 a.m., Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco from January 7 to 10, 2008.

Dr. Zerbe will present an update on clinical development programs at QuatRx including a review of the positive results from a pivotal phase 3 trial for Ophena(TM) (ospemifene) for the treatment of postmenopausal vaginal syndrome (PVS). Results of the pivotal phase 3 trial for Ophena(TM) were announced by QuatRx on January 3, 2008.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active clinical development and two preclinical development programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. Asord(TM) (becocalcidiol), a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, CollaGenex Pharmaceuticals, Inc. QuatRx's two preclinical small molecule programs are designed to address common endocrine disorders in women and men. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs

Post Your Comments:

(Date:12/14/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, owing to the launches ... market will increase more than sevenfold from $790 ... in the United States, France, Germany, Italy, Spain, ... Pharmacor report entitled Atrial Fibrillation finds ...

(Date:12/14/2009)... -- , - Results From a ... Arthritis in Seven Major Industrialized Countries , , ... say their disease, impacts their ... living with rheumatoid arthritis find shopping for gifts, ... presents most, difficult to do, ...

(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...

(Date:12/11/2009)... have discovered a new explanation for differences in the severity ... a certain gene, the more serious the handicap. The genetic ... that it is the amount of copies of the GDI1 ... the American Journal of Human Genetics , and are ... connected to VIB, a life sciences research institute in Flanders, ...

Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2 Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2 Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3 Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4 Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2 Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3 Amount of gene surplus determines severity of mental retardation in males 2

[0] The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 [0] Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas [0] Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering [0] Amount of gene surplus determines severity of mental retardation in males

... for Lead Discovery, COPENHAGEN, June 18 ... a drug discovery collaboration with Merck & Co.,Inc., ... discovery,technology to identify novel small molecule leads against ... platform uses innovative DNA,labeling to allow fragment-based drug ...

... EAST HARTFORD, Conn., June 17 The Connecticut,Technology ... awards program in,partnership with accounting firm UHY LLP this ... Connecticut. Companies will be,recognized on the basis of revenue ... of $50,000 and minimum revenues of $3 million in,the ...

... 17 Edwards Lifesciences,Corporation (NYSE: EW ), ... advanced cardiovascular disease, is scheduled to participate in ... White Elephant,Hotel in Nantucket, Massachusetts on Tuesday, June ... corporate vice president, chief,financial officer & treasurer, is ...

Other Biology Technology:Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2 Connecticut Technology Council to Recognize Fast Growing Technology Companies 2 Edwards Lifesciences to Present at the 18th Annual Wachovia Nantucket Equity Conference 2

Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.Connecticut Technology Council to Recognize Fast Growing Technology Companies Edwards Lifesciences to Present at the 18th Annual Wachovia Nantucket Equity Conference

(Date:12/11/2009)... degrade the diverse types of defective proteins and thus ... C. Horn, Professor Thomas Sommer, Professor Udo Heinemann and ... Molecular Medicine (MDC) Berlin-Buch, Germany, have now found a ... that plays a critical role in the quality control ... and disposal of various defectively produced proteins. ( Molecular ...

(Date:12/11/2009)... the 4th edition of Springer,s classic reference and textbook ... Victor A. McKusick Leadership Award. The prize, which recognizes ... genetics, was presented to him at the 59th Annual ... 24 October 2009 in Honolulu, Hawaii. , Motulsky is ... University of Washington in Seattle. One of the founding ...

(Date:12/11/2009)... release is available in German . ... to more plant introductions than extinctions, plant communities ... The same species are occurring more frequently, whereas ... only the biological communities that are becoming increasingly ... These processes have led to a loss of ...

[0] MDC researchers identify a scaffold regulating protein disposal [0] Editor of Springer classic human genetics reference receives prize [0] Europe's flora is becoming impoverished

... than once, according to research published this week by Queen ... the ability to echolocate do not all group together in ... to their non-echolocating cousins, the fruit bats. This has raised ... than once, or whether the fruit bats somehow lost their ...

... Scientists at the M.D. Anderson Cancer Center have ... for African Americans that suggests a greater risk from ... published in the September issue of Cancer Prevention ... Cancer Research. , Etzel and colleagues analyzed data ...

... and industries around the world will collaborate on ... to develop implantable devices made from biodegradable metals. ... physical changes in a patient,s body and dissolve ... stents, and other devices would reduce the follow-up ...

Other Biology News:Molecular evolution is echoed in bat ears 2 African-Americans have unique lung cancer risks from chronic obstructive pulmonary disease 2 Project aims to reduce complications, multiple surgeries with biodegradable implantable devices 2 Project aims to reduce complications, multiple surgeries with biodegradable implantable devices 3 Project aims to reduce complications, multiple surgeries with biodegradable implantable devices 4

Molecular evolution is echoed in bat ears African-Americans have unique lung cancer risks from chronic obstructive pulmonary disease Project aims to reduce complications, multiple surgeries with biodegradable implantable devices

... the Moticam 2300 camera (MC2300) attaches to ... or trinocular port. Included in the standard ... 2.0ML software offers quick and accurate image ... resolution for examination or documentation purposes. The ...

... an aqueous solution that contains a purified ... a PBS buffer (phosphate buffered saline), pH ... not contain a preservative. StabilCoat Immunoassay ... dried protein components in immunoassays and can ...

Mouse monoclonal antibody to PARK2 - Parkinson disease (autosomal recessive, juvenile) 2, parkin...

Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...

Biology Products:

Moticam 2300 from Motic Instruments, Inc.StabilCoat Immunoassay Stabilizer from SurModics, Inc.Mouse Anti-Human PARK2 Monoclonal Antibody, Unconjugated, Clone 1H4 from Novus Biologicals Rabbit Anti-NMDA NR2B, phospho (Tyr1336) Polyclonal Antibody, Unconjugated from Novus Biologicals

QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare ...( QuatRx CEO will present an update on...)